JP2024508088A - 全身送達及び抗腫瘍活性の向上のための腫瘍溶解性ウイルス - Google Patents

全身送達及び抗腫瘍活性の向上のための腫瘍溶解性ウイルス Download PDF

Info

Publication number
JP2024508088A
JP2024508088A JP2023541092A JP2023541092A JP2024508088A JP 2024508088 A JP2024508088 A JP 2024508088A JP 2023541092 A JP2023541092 A JP 2023541092A JP 2023541092 A JP2023541092 A JP 2023541092A JP 2024508088 A JP2024508088 A JP 2024508088A
Authority
JP
Japan
Prior art keywords
hsv
oncolytic
glycoprotein
fuson
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541092A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508088A5 (cg-RX-API-DMAC7.html
Inventor
ショーン・ジャン
シンピン・フ
Original Assignee
ユニバーシティ オブ ヒューストン システム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ ヒューストン システム filed Critical ユニバーシティ オブ ヒューストン システム
Publication of JP2024508088A publication Critical patent/JP2024508088A/ja
Publication of JP2024508088A5 publication Critical patent/JP2024508088A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023541092A 2021-02-09 2022-02-08 全身送達及び抗腫瘍活性の向上のための腫瘍溶解性ウイルス Pending JP2024508088A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163200011P 2021-02-09 2021-02-09
US63/200,011 2021-02-09
US202163263528P 2021-11-04 2021-11-04
US63/263,528 2021-11-04
PCT/US2022/015703 WO2022173767A1 (en) 2021-02-09 2022-02-08 Oncolytic virus for systemic delivery and enhanced anti-tumor activities

Publications (2)

Publication Number Publication Date
JP2024508088A true JP2024508088A (ja) 2024-02-22
JP2024508088A5 JP2024508088A5 (cg-RX-API-DMAC7.html) 2025-02-18

Family

ID=80623426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541092A Pending JP2024508088A (ja) 2021-02-09 2022-02-08 全身送達及び抗腫瘍活性の向上のための腫瘍溶解性ウイルス

Country Status (6)

Country Link
US (1) US20240123004A1 (cg-RX-API-DMAC7.html)
EP (1) EP4291216A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024508088A (cg-RX-API-DMAC7.html)
AU (1) AU2022219921A1 (cg-RX-API-DMAC7.html)
CA (1) CA3202849A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022173767A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230295661A1 (en) * 2022-03-16 2023-09-21 University Of Houston System Persistent hsv gene delivery system

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008546801A (ja) * 2005-06-23 2008-12-25 ベイラー カレッジ オブ メディスン 癌の治療のための単純ヘルペスウイルス2型変異体の使用
JP2019500909A (ja) * 2016-01-08 2019-01-17 レプリミュン リミテッド 腫瘍溶解性ウイルス株
WO2019232379A1 (en) * 2018-05-31 2019-12-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Antigenically stealthed oncolytic viruses
JP2020525435A (ja) * 2017-06-21 2020-08-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 血液悪性腫瘍に対するcd47標的化治療のための投与パラメータ

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
DK0604662T3 (da) 1992-07-07 2008-10-20 Japan Tobacco Inc Fremgangsmåde til transformering af monocotyledon
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
AU670316B2 (en) 1992-07-27 1996-07-11 Pioneer Hi-Bred International, Inc. An improved method of (agrobacterium)-mediated transformation of cultured soybean cells
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US6013265A (en) 1996-10-22 2000-01-11 University Of Maryland, Baltimore Vaccine composition for herpes simplex virus and methods of using
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US20150246086A1 (en) 2005-06-23 2015-09-03 The University Of Houston System Use of Mutant Herpes Simplex Virus-2 for Cancer Therapy
WO2012071276A1 (en) 2010-11-23 2012-05-31 Xiaoliu Zhang Oncolytic virus as an inducer for innate antitumor immunity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008546801A (ja) * 2005-06-23 2008-12-25 ベイラー カレッジ オブ メディスン 癌の治療のための単純ヘルペスウイルス2型変異体の使用
JP2019500909A (ja) * 2016-01-08 2019-01-17 レプリミュン リミテッド 腫瘍溶解性ウイルス株
JP2020525435A (ja) * 2017-06-21 2020-08-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 血液悪性腫瘍に対するcd47標的化治療のための投与パラメータ
WO2019232379A1 (en) * 2018-05-31 2019-12-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Antigenically stealthed oncolytic viruses

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FAN Q. ET AL.: "Natural selection of glycoprotein B mutations that rescue the small-plaque phenotype of fusion-impai", MBIO, vol. 9, 5, JPN7026000341, 16 October 2018 (2018-10-16), pages 01948 - 18, ISSN: 0005787699 *
FU X. ET AL.: "Genetically coating oncolytic herpes simplex virus with CD47 allows efficient systemic delivery and", ONCOTARGET, vol. 9, 77, JPN7026000338, 2 October 2018 (2018-10-02), pages 34543 - 34553, ISSN: 0005787696 *
HUA L. ET AL.: "Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinic", EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 19, 8, JPN7026000339, 13 May 2019 (2019-05-13), pages 845 - 854, ISSN: 0005787697 *
LIU XQ. ET AL.: "Oncolytic herpes simplex virus tumor targeting and neutralization escape by engineering viral envero", DRUG DELIVERY, vol. 25, 1, JPN7026000337, 4 December 2018 (2018-12-04), pages 1950 - 1962, ISSN: 0005787695 *
PASSARO C. ET AL.: "Arming an oncolytic herpes simplex virus type 1 with a single-chain fragment variable antibody again", CLINICAL CANCER RESEARCH, vol. 25, 1, JPN7026000340, 2 October 2018 (2018-10-02), pages 290 - 299, ISSN: 0005787698 *
RAUCH DA. ET AL.: "Mutations in herpes simplex virus glycoprotein D distinguish entry of free virus from cell-cell spre", JOURNAL OF VIROLOGY, vol. 74, 24, JPN7026000342, December 2000 (2000-12-01), pages 11437 - 11446, ISSN: 0005787700 *

Also Published As

Publication number Publication date
CA3202849A1 (en) 2022-08-18
EP4291216A1 (en) 2023-12-20
AU2022219921A1 (en) 2023-06-29
US20240123004A1 (en) 2024-04-18
WO2022173767A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
JP5284780B2 (ja) 癌の治療のための単純ヘルペスウイルス2型変異体の使用
AU2003258060B2 (en) Potent oncolytic herpes simplex virus for cancer therapy
US12414973B2 (en) Antigenically stealthed oncolytic viruses
KR20230117107A (ko) 단백질 페이로드 방출
MXPA02002142A (es) Promotor especifico de la celula y/o especifico del tumor, que re-selecciona como objetivo la expresion del gen gamma 35.5 de herpes.
US20240123004A1 (en) Oncolytic virus for systemic delivery and enhanced anti-tumor activities
JP7460850B2 (ja) 多重標的化組換えヘルペスシンプルレックスウイルス及びその用途
US20150246086A1 (en) Use of Mutant Herpes Simplex Virus-2 for Cancer Therapy
CN116782917A (zh) 用于全身递送的溶瘤病毒及增强的抗肿瘤活性
US20230295661A1 (en) Persistent hsv gene delivery system

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260803